Founded in 2016 by University of Pennsylvania researchers Andrew Tsourkas and James Hui, Philadelphia-based AlphaThera develops antibody-labeling reagents and conjugation services built around its oYo-Link® site-specific technology. The platform uses light-activated covalent attachment at an antibody’s Fc region, allowing researchers to prepare uniform conjugates with less than 30 seconds of hands-on work and applications ranging from multiplex assays to single-cell analysis. AlphaThera also supports custom and larger-scale projects, including antibody-oligonucleotide conjugation and labeling quantities of 1 gram or more.